PO.MCB08.02 · 分子与细胞生物学
癌症基因组图谱(TCGA)全基因组测序数据集中的种系易感性
Germline predisposition in The Cancer Genome Atlas (TCGA) whole-genome sequencing datasets
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
癌症基因组图谱(TCGA)的目标一直是持续表征各种恶性肿瘤的基因组和转录组图谱。在本分析中,我们评估了来自一组先前已测序的成人癌症患者的匹配肿瘤-正常全基因组测序(WGS)数据,以识别种系致病变异。这些最新的TCGA数据由来自不同祖源背景、患有实体瘤和淋巴系统肿瘤的癌症患者及其患者匹配的正常样本(由血液或组织构成)组成。我们现已获得来自超过8,000个样本的高质量肿瘤和正常WGS数据,其中正常样本主要来源于患者匹配的血液样本。为发现遗传与癌症易感性之间的新联系,我们正在分析已知癌症基因以及可能被遗漏或先前无法通过外显子组或低覆盖度基因组研究评估的复发性突变基因中的种系变异——包括单核苷酸变异(SNVs)和结构变异(SVs)。我们进行了初步分析,重点识别按照美国医学遗传学与基因组学学会指南分类的癌症易感基因中的致病或可能致病(P/LP)变异。这次对大多数样本的初步分析证实,在整个队列中的经典癌症易感基因中存在P/LP变异,包括BRCA1、BRCA2、ATM以及其他对错配修复和DNA修复通路至关重要的基因。在各队列中,我们在少于10%的所有病例的已确立癌症易感基因中识别出已知的P/LP种系变异,其中变异数量最多的位于BRCA1/2,与既往发表的工作一致。P/LP变异的患病率在各癌症类型间并不一致,一些类型显示出富集(包括乳腺癌),而其他癌症类型(如低级别胶质瘤)则表现出低于平均水平的患病率。这些发现凸显了种系易感性高度可变、肿瘤特异性的图谱。我们持续将这一全面的WGS数据集作为种系-体细胞相互作用后续分析的关键资源加以利用。我们正在积极研究这些种系P/LP变异如何塑造肿瘤的体细胞突变图谱并促进肿瘤发生。我们还在研究单倍型特异性的拷贝数改变是否有助于所识别的种系癌症风险等位基因的致病性。进一步的工作包括表征先前在外显子组或低覆盖度WGS研究中无法获取的结构性和复杂非编码致病变异。
查看英文原文 English abstract
The goal of The Cancer Genome Atlas (TCGA) has been to continually characterize the genomic and transcriptomic landscapes across diverse malignancies. In this analysis, we assess matched tumor-normal Whole-Genome Sequencing (WGS) data from a previously sequenced set of adult cancer patients to identify germline pathogenic variations. These latest TCGA data consist of cancer patients from varied ancestral backgrounds with solid tumors and lymphoid cancers and patient-matched normal samples, consisting of blood or tissue. We have now obtained high-quality tumor and normal WGS data from over 8,000 samples, including normal samples derived mainly from the patient-matched blood samples. To discover novel links between genetics and cancer predisposition, we are analyzing germline variants-including single-nucleotide variants (SNVs) and structural variants (SVs)-in known cancer genes, as well as in genes with recurrent mutations that may have been missed or previously could not be assessed using exome or low-coverage genome studies.We have conducted a preliminary analysis focused on identifying Pathogenic or Likely Pathogenic (P/LP) variants, classified according to American College of Medical Genetics and Genomics guidelines, in cancer predisposition genes. This initial pass on a majority of samples confirmed the presence of P/LP variants across the cohort in canonical cancer predisposition genes, including BRCA1 , BRCA2 , ATM , and other genes integral to the mismatch and DNA repair pathways. Across cohorts, we identified known P/LP germline variants in established cancer predisposition genes in less than 10% of all cases, with the largest number of variants identified in BRCA1/2 , aligning with previous published work. The prevalence of P/LP variants was not uniform across cancer types, with some showing an enrichment, including breast cancer, while other cancer types, like low-grade gliomas, demonstrated a lower prevalence than the average. These findings underscore the highly variable, tumor-specific landscape of germline predisposition.We continue to leverage this comprehensive WGS dataset as a key resource for ongoing analyses of germline-somatic interactions. We are actively investigating how these germline P/LP variants shape the tumor's somatic mutational landscape and contribute to oncogenesis. We are also investigating whether haplotype-specific copy number alterations contribute to the pathogenicity of identified germline cancer risk alleles. Further work includes characterizing both structural and complex non-coding pathogenic variants that were previously inaccessible in exome or low-coverage WGS studies.
利益披露 Disclosure
R. Kim, None..
O. Hirschi, None..
M. Leventhal, None..
C. Bao, None..
H. Park, None..
G. Lee, None..
W. Lee, None..
J. Lee, None..
Y. Lee, None..
B. Lee, None..
D. Lehotzky, None..
R. Solan, None..
A. Kowalewski, None..
X. Loinaz, None..
V. Narasimha Swamy, None..
D. I. Heiman, None..
S. Van Seters, None..
S. Belkin, None..
S. Wiseman, None.
A. D. Cherniack,
Bayer ).
L. Corchete Sanchez, None..
B. Danysh, None..
Z. Everton, None..
C. Stewart, None..
H. Tomono, None..
G. Wang, None.
E. Rheinbay,
Inocras E.R. receives research funding from Inocras, Inc.
G. Getz,
IBM ).
Pharmacyclics/Abbvie ).
Bayer ).
Genentech ).
Calico ).
Ultima Genomics ).
Inocras ).
Google ).
Kite ).
Novartis ).
Scorpion Therapeutics Stock Option, He is a founder, consultant, and holds privately held equity in Scorpion Therapeutics.
Predicta Biosciences Stock Option, He is also a founder of, and holds privately held equity in, Predicta Biosciences.
Antares Therapeutics Stock Option.
C. Zhang, None..
M. L. Meyerson, None..
Y. Ju, None.